Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
This product is currently not marketed in the UK. In the absence of a submission from the holder of the marketing authorisation, ferric citrate (Fexeric®) cannot be endorsed for use within NHS Wales for the control of hyperphosphataemia in adult patients with chronic kidney disease. |
||
|
||
Medicine details |
||
| Medicine name | ferric citrate (Fexeric®) | |
| Formulation | 1 g film-coated tablet | |
| Reference number | 1188 | |
| Indication | Control of hyperphosphataemia in adult patients with chronic kidney disease |
|
| Company | Keryx Biopharmaceuticals Inc | |
| BNF chapter | Nutrition & blood | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 06/01/2016 | |